CYP3A4 and seasonal variation in vitamin D status in addition to CYP2D6 contribute to therapeutic endoxifen level during tamoxifen therapy (Q51072700)

28 March 2018

title

CYP3A4 and seasonal variation in vitamin D status in addition to CYP2D6 contribute to therapeutic endoxifen level during tamoxifen therapy (English)

1 reference

28 March 2018

0 references

1 reference

Wendy A Teft

1

1 reference

28 March 2018

Inna Y Gong

2

1 reference

28 March 2018

Brian Dingle

3

1 reference

28 March 2018

Kylea Potvin

4

1 reference

28 March 2018

Jawaid Younus

5

1 reference

28 March 2018

Theodore A Vandenberg

6

1 reference

28 March 2018

Muriel Brackstone

7

1 reference

28 March 2018

Francisco E Perera

8

1 reference

28 March 2018

Yun-Hee Choi

9

1 reference

28 March 2018

Guangyong Zou

10

1 reference

28 March 2018

Robin M Legan

11

1 reference

28 March 2018

Rommel G Tirona

12

1 reference

28 March 2018

Richard B Kim

13

1 reference

28 March 2018

language of work or name

English

0 references

publication date

12 April 2013

1 reference

28 March 2018

Breast Cancer Research and Treatment

published in

1 reference

28 March 2018

volume

139

1 reference

28 March 2018

issue

1

1 reference

28 March 2018

page(s)

95-105

1 reference

28 March 2018

Pharmacogenetics of endocrine therapy for breast cancer

cites work

1 reference

https://api.crossref.org/works/10.1007/S10549-013-2511-4

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-013-2511-4

CYP2D6 and tamoxifen: DNA matters in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-013-2511-4

Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-013-2511-4

CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-013-2511-4

Activity Levels of Tamoxifen Metabolites at the Estrogen Receptor and the Impact of Genetic Polymorphisms of Phase I and II Enzymes on Their Concentration Levels in Plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-013-2511-4

Drug interactions and pharmacogenomics in the treatment of breast cancer and depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-013-2511-4

The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-013-2511-4

CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-013-2511-4

Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-013-2511-4

Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-013-2511-4

Tamoxifen and CYP2D6: a contradiction of data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-013-2511-4

Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-013-2511-4

Endoxifen, the Active Metabolite of Tamoxifen, Is a Substrate of the Efflux Transporter P-Glycoprotein (Multidrug Resistance 1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-013-2511-4

Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-013-2511-4

Determination of clinically therapeutic endoxifen concentrations based on efficacy from human MCF7 breast cancer xenografts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-013-2511-4

Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-013-2511-4

The P450 oxidoreductase genotype is associated with CYP3A activity in vivo as measured by the midazolam phenotyping test

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-013-2511-4

Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-013-2511-4

4β-Hydroxycholesterol, an endogenous marker of CYP3A4/5 activity in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-013-2511-4

Intestinal CYP3A4 and midazolam disposition in vivo associate with VDR polymorphisms and show seasonal variation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-013-2511-4

CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSG) 8.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-013-2511-4

CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-013-2511-4

The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-013-2511-4

Drug metabolism and variability among patients in drug response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-013-2511-4

Genetic contribution to variable human CYP3A-mediated metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-013-2511-4

Effects of CYP induction by rifampicin on tamoxifen exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-013-2511-4

Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-013-2511-4

Ultraviolet sunlight exposure during adolescence and adulthood and breast cancer risk: a population-based case-control study among Ontario women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-013-2511-4

Serum 25-hydroxyvitamin D and postmenopausal breast cancer survival: a prospective patient cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-013-2511-4

Up-regulation of transporters and enzymes by the vitamin D receptor ligands, 1alpha,25-dihydroxyvitamin D3 and vitamin D analogs, in the Caco-2 cell monolayer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-013-2511-4

Addressing the health benefits and risks, involving vitamin D or skin cancer, of increased sun exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-013-2511-4

Dextromethorphan as a phenotyping test to predict endoxifen exposure in patients on tamoxifen treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10549-013-2511-4

10.1007/S10549-013-2511-4

21 January 2018

Identifiers

DOI

1 reference

28 March 2018

1 reference

28 March 2018